Navigation Links
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
Date:2/12/2009

our current pipeline of transplant/oncology products. We are committed to the success of this collaboration in the development of this important compound."

"We are very pleased to begin this partnership with Sigma-Tau," said Christopher J. Schaber, PhD, President and CEO of DOR. "Sigma-Tau's premium investment in DOR shares gives us the cash necessary to complete our upcoming confirmatory Phase 3 clinical trial of orBec(R) in GI GVHD. This partnership will also provide for the launch and commercialization of orBec(R) in North America, without any further related expense to DOR or its shareholders. It also provides us with the potential for ongoing development funding across multiple indications for orBec(R) and oral BDP."

Dr. Schaber continued, "We have known Sigma-Tau for a long time, as they have been an investor in DOR for several years. We are confident in their strong commitment to working with other biotech companies, and recognize their expertise in commercializing orphan products. We welcome them to our Board of Directors. Together with Sigma-Tau, we are optimistic about the prospects for our orBec(R) and Oral BDP pipelines and look forward to the possibility of having these products approved by the FDA."

About orBec(R) and Oral BDP

Two prior randomized, double-blind, placebo-controlled Phase 2 and 3 clinical trials support orBec's(R) ability to provide clinically meaningful outcomes when compared with the current standard of care, including a lowered exposure to systemic corticosteroids following allogeneic transplantation. Currently, there are no approved products to treat GI GVHD. The first trial was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center. The second trial was a 129-patient pivotal Phase 3 multi-center clinical trial of orBec(R) conducted at 16 leading bone marrow/stem cell t
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
2. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
3. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
4. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
6. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
7. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
8. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
9. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
10. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Exposed Skin Care has finally been released after much anticipation ... finally achieve the clear, beautiful skin they have always dreamed ... system combines the power of science and nature to both ... , After a quick review of Exposed Skin ... most effective available on the market to cure acne both ...
(Date:6/18/2013)... Recent studies linking bullying and depression, coupled with ... people, led the Centers for Disease Control and ... focus on these issues. This panel synthesized the ... involvement in bullying and suicide-related behaviors. Three themes ... public health problem, with widespread and often harmful ...
(Date:6/18/2013)... An apple a day might really keep ... with breast cancer, she chose a different method for ... Myself Cancer, I Can Take It Away!: Alternatives Brought ... explains how changing her physical, mental and emotional diet ... made to feel fearful when diagnosed with a disease ...
(Date:6/18/2013)... Cheap Concert Tickets has released additional inventories ... gets underway in July. Soccer fans can add code ... , The popularity and hype of soccer has ... the hype of the game triggered the sports-minded citizens of ... the veins of fans from the Caribbean. The adrenalin ...
(Date:6/18/2013)... As obesity rates sky rocket in the United ... during childbirth comes as no shock. Forceps are surgical equipment ... she is unable to do so herself and although they ... rates of complication for both the mother and the baby. ... and child, forceps births add to the pressure of healthcare ...
Breaking Medicine News(10 mins):Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:Bullying and suicide among youth is a public health problem 2Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 2Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 3Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2
... Mayo Clinic researchers have discovered that a chemical known ... for the effectiveness of tamoxifen in treating breast cancer, ... unexpected way. , Their study, being presented at the ... (CTRC-AACR) 31st annual San Antonio Breast Cancer Symposium, finds ...
... their lower back pain are better off than those who ... a University of Alberta study. , The study, done in ... cent improvement in pain and function levels for people with ... of resistance training using dumbbells, barbells and other load-bearing exercise ...
... Liverpool Associates in Tropical Health (LATH), a consulting arm ... a 10 million contract to manage a programme of ... initiative in Malawi. , Led by the National ... 5 year programme supported by the Wellcome Trust, the ...
... large proteomics study on the brains of newborn mice ... obstetric or pediatric medicine can have profound and long-term ... study, appearing in the December issue of Molecular ... the developing nervous system and reinforces the use of ...
... TCM Inc. of West Chester, PA ... named PCM Solutions, LLC, with Nalco Company ... the process industries, such as chemical and petrochemical manufacturing, ... paper manufacturing, food and beverage production, and various other ...
... Enhances First Global Medical Donations Map , ... The Partnership for Quality Medical Donations (PQMD) Mapping Tool, ... to information about the medical product donations being made ... to the world,s most vulnerable populations. Both the ...
Cached Medicine News:Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 2Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 3Health News:LATH wins contract to boost health research capacity in Malawi 2Health News:The profound effects of numbing agents 2Health News:Haas TCM Inc. Forms PCM Solutions, LLC, a Joint Venture With Nalco Company, to Provide Chemical Management Services (CMS) to the Process Industries 2Health News:Global Mapping Tool Demonstrates Medical Donation Impact 2Health News:Global Mapping Tool Demonstrates Medical Donation Impact 3
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
(Date:6/18/2013)... 18, 2013  Actavis, Inc. (NYSE: ACT ) ... the U.S. Securities and Exchange Commission (SEC) a registration statement ... Warner Chilcott plc (NASDAQ: WCRX ), ... Warner Chilcott (the "Form S-4"). As previously ... have entered into a definitive agreement pursuant to which ...
(Date:6/18/2013)...  Recent regulatory and budget challenges have made it ... large pharmaceutical companies to effectively educate doctors and other ... their new products. With the pressure to reduce budgets ... these "Med Ed" groups find practical, economical ... the changes that are transforming the Medical Education area ...
Breaking Medicine Technology:Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2
... May 5, 2011 Novartis Pharmaceuticals Corporation ("Novartis") announced ... approved Afinitor® (everolimus) tablets for the treatment of progressive ... unresectable, locally advanced or metastatic disease(4). This marks the ... in the US in nearly 30 years(5). ...
... FRANCISCO, May 5, 2011 Cardiac Network, Inc. (Other OTC: ... a 1-for-750 reverse stock split (the "Reverse Stock Split"). The ... business and trading on May 6, 2011 (the "Effective Date"). ... changed from "CNWI" to "CNWID" for approximately 20 business days, ...
Cached Medicine Technology:Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 2Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 3Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 4Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 5Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 6Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 7Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 8Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 9Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 10Cardiac Network Announces Reverse Stock Split 2
Hollow Copper Tube with Suction Port 16.5....
Aluminum Stylette 16 with Adjustable Stop....
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
Aluminum Stylette 16....
Medicine Products: